Novo's Ozempic, Wegovy picked for US Medicare price negotiations
Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for Medicare price negotiations for 2027, the U.S. government said on Friday, part of a law pharmaceutical companies have pledged to revisit with the Trump administration.
In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...
1d
People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.
Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight ...
The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare ...
We recently published a list of These 10 Firms Took A Hit on Friday. In this article, we are going to take a look at where ...
Stocks rallied sharply Friday and the S&P 500 was on pace for its best week since early November.These stocks were making ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback